European Medicines Agency Clears 12 New Treatments for EU Market Rollout

The European Medicines Agency’s scientific committee endorsed 12 new medicines for approval across the European Union during its September 2026 meeting. The Committee for Medicinal Products for Human Use—known in Brussels shorthand as the CHMP—also gave positive scientific opinions to extend the use of 11 existing drugs for additional medical conditions. Among the newly recommended therapies is Frehemgo (denecimig), developed by pharmaceutical firm Novo Nordisk, which is designed to prevent bleeding episodes in individuals living with haemophilia A.

For patients across all 27 EU member states, a green light from the regulator is the pivotal hurdle before a drug can reach local clinics and pharmacies. For individuals managing haemophilia A, the endorsement of Frehemgo provides a new preventive option for a severe chronic condition. Meanwhile, backing extensions of indication for 11 existing medicines allows doctors to prescribe established treatments to entirely new patient groups, expanding care options without waiting for new compounds to clear years of development.

In the EU’s drug approval machinery, the European Medicines Agency acts as the scientific gatekeeper, but it does not technically issue final commercial licenses. The CHMP handles the technical legwork, parsing clinical trial data to determine whether a medicine's therapeutic benefit outweighs its risks. Once the committee issues a positive opinion, the file travels from Amsterdam to the European Commission in Brussels, which holds the legal power to grant a binding, bloc-wide marketing authorisation. While the Commission could theoretically reject the advice, overruling the scientific consensus of the EMA is virtually unheard of in Brussels. It remains one of the Union's sleeker procedures: scientists handle the medicine, and civil servants rubber-stamp the law.

The CHMP recommendations now go to the European Commission for official adoption of marketing authorisations. Once the Commission formally signs off, each drug gains single-market access. The focus then moves to national capitals, where individual health ministries and pricing authorities will negotiate drug pricing and decide whether to cover the treatments under national health insurance schemes.